Cite
HARVARD Citation
Park, S. et al. (2021). Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial‐unfit patients and subsequent therapy. British journal of haematology. pp. 101-112. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Park, S. et al. (2021). Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial‐unfit patients and subsequent therapy. British journal of haematology. pp. 101-112. [Online].